FDA approves new treatment to reduce the risk of breast cancer returning
The U.S. Food and Drug Administration has approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
More... |
All times are GMT -7. The time now is 10:09 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021